公开(公告)号：US20210079051A1

公开(公告)日：2021-03-18

申请号：US17094968

申请日：2020-11-11

Applicant: AMGEN INC.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. ZHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20240368236A1

公开(公告)日：2024-11-07

申请号：US18639202

申请日：2024-04-18

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20180079790A1

公开(公告)日：2018-03-22

申请号：US15826442

申请日：2017-11-29

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20170275370A1

公开(公告)日：2017-09-28

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/26 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20250121056A1

公开(公告)日：2025-04-17

申请号：US18982197

申请日：2024-12-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle M. VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K39/395 ,  A61K47/68 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20220025059A1

公开(公告)日：2022-01-27

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20190315822A1

公开(公告)日：2019-10-17

申请号：US16416050

申请日：2019-05-17

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Kenneth W. WALKER ,  Bryan LEMON

IPC: C07K14/475 ,  A61K38/00 ,  C07K14/51 ,  A61K39/00 ,  A61K38/17 ,  A61K38/18 ,  C07K14/495 ,  A61K38/16

Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20170291929A1

公开(公告)日：2017-10-12

申请号：US15625891

申请日：2017-06-16

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Kenneth W. WALKER ,  Bryan LEMON

IPC: C07K14/475 ,  A61K39/00

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K38/18 ,  A61K39/0005 ,  A61K2039/6056 ,  C07K14/495 ,  C07K14/51 ,  C07K2319/30

Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.